Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

11/12/24 2:31:31 PM ET

Medical Specialities

Health Care

Get the next $CLOV alert in real time by email

SC 13G/A 1 UnitedStates_13G__CloverHeal.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* (Name of Issuer) Clover Health Investments Corp (Title of Class of Securities) Common Stock (CUSIP Number) 18914F103 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 18914F103 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 85,111 (7) Sole dispositive power 18,740,498 (8) Shared dispositive power 458,216 (9) Aggregate amount beneficially owned by each reporting person 19,198,714 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 4.70% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Clover Health Investments Corp Item 1(b) Address of issuer's principal executive offices: 3401 Mallory Ln Suite 210 Franklin, TN 37067 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 18914F103 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 19,198,714 (b) Percent of class: 4.70% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 19,198,714 (b) Percent of class: 4.70% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 85,111 (iii) Sole power to dispose or to direct the disposition of: 18,740,498 (iv) Shared power to dispose or to direct the disposition of: 458,216 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, t* he securities referred to above were not acquired and are not held for the pur* pose of or with the effect of changing or influencing the control of the issuer* of the securities and were not acquired and are not held in connection with or* as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 12, 2024 THE VANGUARD GROUP By: /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration

Get the next $CLOV alert in real time by email

Recent Analyst Ratings for

$CLOV

Date	Price Target	Rating	Analyst
12/17/2024	$6.00	Buy	Craig Hallum
10/7/2024	$4.00	Neutral	UBS
2/25/2022	$3.00 → $2.50	Market Perform	SVB Leerink
2/2/2022	$7.00 → $3.00	Underperform → Market Perform	Cowen & Co.
2/2/2022	$6.00	Buy	Canaccord Genuity
1/19/2022	$3.00	Market Perform	SVB Leerink
1/10/2022	$9.00 → $3.50	Neutral	Citigroup
1/7/2022	$9.00 → $3.50	Neutral → Underperform	Credit Suisse

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

Chat with this insight

Recent Analyst Ratings for $CLOV

$CLOV Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Garipalli Vivek bought $999,596 worth of shares (531,700 units at $1.88), increasing direct ownership by 61% to 1,409,267 units (SEC Form 4)

Director Garipalli Vivek bought $1,000,426 worth of shares (877,567 units at $1.14) (SEC Form 4)

Loengard Anna U bought $25,672 worth of shares (27,085 units at $0.95) (SEC Form 4)

$CLOV Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Garipalli Vivek converted options into 1,670,965 shares and covered exercise/tax liability with 1,670,965 shares (SEC Form 4)

General Counsel & Secretary Soares Karen covered exercise/tax liability with 4,308 shares, decreasing direct ownership by 0.31% to 1,386,061 units (SEC Form 4)

CEO, Medicare Advantage Reynoso Jamie L. covered exercise/tax liability with 17,142 shares, decreasing direct ownership by 0.52% to 3,307,254 units (SEC Form 4)

$CLOV Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Craig Hallum initiated coverage on Clover Health with a new price target

UBS initiated coverage on Clover Health with a new price target

SVB Leerink reiterated coverage on Clover Health Investments with a new price target

$CLOV SEC Filings

Clover Health Investments Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Clover Health Investments Corp.

Clover Health Investments Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$CLOV Press Releases

Fastest customizable press release news feed in the world

Clover Health Reports 27% Growth in Medicare Advantage Membership, Surpassing 100,000 Lives After Strong Annual Election Period

Counterpart Health Deploys Counterpart Assistant with Leading Accountable Care Organization

Clover Health to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

$CLOV Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

SEC Form SC 13G/A filed by Clover Health Investments Corp. (Amendment)

$CLOV Insider purchases explained

Analytical look into recent insider purchases

Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

$CLOV Financials

Live finance-specific insights

Clover Health Reports Strong Third Quarter 2024 Financial Results; Highlights Differentiated Market Opportunity to Grow Membership

Clover Health to Report Third Quarter 2024 Financial Results on November 6

Clover Health Reports Second Quarter 2024 Financial Results; Improves Full-Year Guidance on Strong Performance

$CLOV Leadership Updates

Live Leadership Updates

Counterpart Health Names David Tsay M.D., Ph.D as Chief Medical Officer

Clover Health Appoints Seasoned Healthcare Executive as Chief Operating Officer for Medicare Advantage Operations

Thomas L. Tran, Former Chief Financial Officer of Molina Healthcare, Joins Clover Health's Board of Directors

Recent Analyst Ratings for
$CLOV

$CLOV
Insider Purchases

$CLOV
Insider Trading

$CLOV
Analyst Ratings

$CLOV
SEC Filings

$CLOV
Press Releases

$CLOV
Large Ownership Changes

$CLOV
Insider purchases explained

$CLOV
Financials

$CLOV
Leadership Updates